Multiple Myeloma Clinical Trials in Iowa City, Iowa

10 studies are recruiting for multiple myeloma in Iowa City, Iowa right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Collection of Tissue Samples for Cancer Research

   Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research …

   Stage

   Not phased

   Ages

   0 and older

   Site

   University of Iowa, Iowa City, Iowa

   Locations

   17 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00900198 on ClinicalTrials.gov

2. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Iowa, Iowa City, Iowa

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

3. A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

   The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilt…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   University of Iowa Hospital and Clinics, Iowa City, Iowa

   Locations

   17 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07149857 on ClinicalTrials.gov

4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Iowa Hospital and Clinics, Iowa City, Iowa

   Locations

   144 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

5. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refr…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Iowa, Iowa City, Iowa

   Locations

   71 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07266441 on ClinicalTrials.gov

6. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Iowa Hospitals and Clinics, Iowa City, Iowa

   Locations

   151 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07518186 on ClinicalTrials.gov

7. A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

   This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Iowa, Iowa City, Iowa

   Locations

   21 in total

   Run by

   C4 Therapeutics, Inc.

   See if you can join NCT07284758 on ClinicalTrials.gov

8. A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

   This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Iowa City, Iowa

   Locations

   13 in total

   Run by

   AstraZeneca

   See if you can join NCT07073547 on ClinicalTrials.gov

9. Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

   This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Iowa Health Care, Iowa City, Iowa

   Run by

   Christopher Strouse

   See if you can join NCT07581704 on ClinicalTrials.gov

10. Sleep Apnea in Patients With MGUS and MM

    This study involves patients with plasma cell dyscrasia including monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM), with and without sleep apnea, who are providing bone marrow specimens. Specimens will be obtained at the time that patients undergo a standard-of-car…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    University of Iowa, Iowa City, Iowa

    Run by

    Michael Tomasson

    See if you can join NCT04114084 on ClinicalTrials.gov